ERBB2 and breast carcinoma: Similar findings were also made by Wu et al. [44], who demonstrated that the PI3K/Aktpathway mediating FOXO1 binding to the MALAT1 promoter can bethe mechanism through which MALAT1 induces EMT and reduces thetrastuzumab sensitivity of HER2+ breast cancer cells [44].